Combination Therapy: An Upcoming Paradigm to Improve Kidney and Cardiovascular Outcomes in Chronic Kidney Disease

This review argues that combining SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone delivers additive, complementary kidney and cardiovascular protection in cardiovascular-kidney-metabolic syndrome and is now supported as a treatment approach.